依普利酮治疗高血压效果如何？

How effective is the treatment of high blood pressure? 

Subgroup analysis of the EPHESUS study also showed that the effect of eplerenone on reducing overall mortality was more obvious in patients with hypertension. A comparative study on the efficacy and tolerability of 499 patients with grade 1 or 2 hypertension who were randomized to receive enalapril or eplerenone showed that at 6 months, enalapril was as effective as eplerenone in reducing systolic blood pressure (eplerenone reduced 14.5 mmHg; enalapril reduced 12.7 mmHg: P=0.199) and diastolic blood pressure (eplerenone reduced 11.2 mmHg; enalapril reduced 11.3 mm Hg; P=0.910). After 12 months, the two groups were also similar (eplerenone -16.5/-13.3mmHg; enalapril -14.8/-14.1mmHg, P values ​​0.251 and 0.331 respectively). Dropout due to adverse events (7.9% for eplerenone and 9.3% for enalapril at 6 months) and treatment failure rates were also equal (23.3% for eplerenone and 22.8% for enalapril at 6 months). About 2/3 of the patients in each group achieved normal blood pressure at 6 months with the above single treatment. In the eplerenone group, the reduction in blood pressure was independent of renin levels, unlike enalapril. Both groups could reduce proteinuria above normal levels, but the eplerenone group was more significant (-61.5% vs -25.7%; P=0.01). Eplerenone can improve the quality of life of patients with left ventricular dysfunction (ejection fraction ≤ 40%). Clinical trials have proven that this product can also be used for congestive heart failure after acute myocardial infarction.

Adverse reactions include dizziness, diarrhea, fatigue, flu-like symptoms, cough, abdominal pain, increased blood cholesterol or triglycerides, increased blood potassium and proteinuria. Rare: Enlarged breasts in men, irregular menstruation and breast pain in women.